Biological and pathobiological functions of gelatinase dimers and complexes

Connective Tissue Research

Volumn 49, Issue 3-4, 2008, Pages 180-184

  Malla, Nabin ^a   Sjøli, Stian ^a   Winberg, Jan Olof ^a   Hadler Olsen, Elin ^a   Uhlin Hansen, Lars ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Dimers; Extracellular Matrix; Matrix Metalloproteinases; Pathobiology

Indexed keywords

CD147 ANTIGEN; CHONDROITIN 4 SULFATE; FETUIN A; GELATINASE A; GELATINASE B; HAPTOGLOBIN; HEPARIN; HERMES ANTIGEN; INTERSTITIAL COLLAGENASE; KU ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEOGLYCAN; STROMELYSIN; SYNDECAN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VITRONECTIN RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CARCINOGENESIS; CARTILAGE DEGENERATION; COMPLEX FORMATION; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HEART INFARCTION; HUMAN; LUNG CARCINOMA; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR VASCULARIZATION;

ALPHA-FETOPROTEINS; ANIMALS; DIMERIZATION; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCANS; HAPTOGLOBINS; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROTEOGLYCANS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 48549105169     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.1080/03008200802151755     Document Type: Article

References (29)

1. Nagase, H., Visse, R. and Murphy, G. (2006) Structure and function of matrix metalloproteinases and TIMPs. 69, pp. 562-573.
2. Cawston, T. E. and Wilson, A. J. (2006) Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. 20, pp. 983-1002.
3. Van Den Steen, P.E., Opdenakker, G., Wormald, M. R., Dwek, R. A. and Rudd, P. M. (2001) Matrix remodelling enzymes, the protease cascade and glycosylation. 1528, pp. 61-73.
4. Bjorklund, M. and Koivunen, E. (2005) Gelatinase-mediated migration and invasion of cancer cells. 1755, pp. 37-69.
5. Hibbs, M. S., Hasty, K. A., Seyer, J. M., Kang, A. H. and Mainardi, C. L. (1985) Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. 260, pp. 2493-2500.
6. Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, L. T. and Marmer, B. L. (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. 267, pp. 4583-4591.
7. Triebel, S., Blaser, J., Reinke, H. and Tschesche, H. (1992) A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. 314, pp. 386-388.
8. Kjeldsen, L., Johnsen, A. H., Sengelov, H. and Borregaard, N. (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. 268, pp. 10425-10432.
9. Olson, M. W., Bernardo, M. M., Pietila, M., Gervasi, D. C., Toth, M., Kotra, L. P., Massova, I., Mobashery, S. and Fridman, R. (2000) Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. 275, pp. 2661-2668.
10. Winberg, J. O., Kolset, S. O., Berg, E. and Uhlin-Hansen, L. (2000) Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. 304, pp. 669-680.
11. Crabbe, T., Ioannou, C. and Docherty, A. J. (1993) Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. 218, pp. 431-438.
12. Ilda, J., Wilhelmson, K. L., Ng, J., Lee, P., Morrison, C., Tam, E., Overall, C. M. and McCarthy, J. B. (2007) Cell surface chondroitin sulfate glycosaminoglycan in melanoma: Role in the activation of pro-MMP-2 (pro-gelatinase A). 403, pp. 553-563.
13. Cha, H., Kopetzki, E., Huber, R., Lanzendorfer, M. and Brandstetter, H. (2002) Structural basis of the adaptive molecular recognition by MMP9. 320, pp. 1065-1079.
14. Van Den Steen, P.E., Van Aelst, I., Hvidberg, V., Piccard, H., Fiten, P., Jacobsen, C., Moestrup, S. K., Fry, S., Royle, L., Wormald, M. R., Wallis, R., Rudd, P. M., Dwek, R. A. and Opdenakker, G. (2006) The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. 281, pp. 18626-18637.
15. Tschesche, H., Zolzer, V., Triebel, S. and Bartsch, S. (2001) The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. 268, pp. 1918-1928.
16. Bannikov, G. A., Mattoon, J. S., Abrahamsen, E. J., Premanandan, C., Green-Church, K. B., Marsh, A. E. and Lakritz, J. (2007) Biochemical and enzymatic characterization of purified covalent complexes of matrix metalloproteinase-9 and haptoglobin released by bovine granulocytes in vitro. 68, pp. 995-1004.
17. Ray, S., Lukyanov, P. and Ochieng, J. (2003) Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. 1652, pp. 91-102.
18. inberg, J. O., Berg, E., Kolset, S. O. and Uhlin-Hansen, L. (2003) Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. 270, pp. 3996-4007.
19. Malemud, C. J. (2006) Matrix metalloproteinases (MMPs) in health and disease: An overview. 11, pp. 1696-1701.
20. Munesue, S., Yoshitomi, Y., Kusano, Y., Koyama, Y., Nishiyama, A., Nakanishi, H., Miyazaki, K., Ishimaru, T., Miyaura, S., Okayama, M. and Oguri, K. (2007) A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. 282, pp. 28164-28174.
21. Yu, Q. and Stamenkovic, I. (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. 13, pp. 35-48.
22. Hemdahl, A. L., Gabrielsen, A., Zhu, C., Eriksson, P., Hedin, U., Kastrup, J., Thoren, P. and Hansson, G. K. (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. 26, pp. 136-142.
23. Zhang, H., Xu, L., Xiao, D., Xie, J., Zeng, H., Wang, Z., Zhang, X., Niu, Y., Shen, Z., Shen, J., Wu, X. and Li, E. (2007) Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: Significant correlation with cell differentiation and tumour invasion. 60, pp. 555-561.
24. Gupta, K., Shukla, M., Cowland, J. B., Malemud, C. J. and Haqqi, T. M. (2007) Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. 56, pp. 3326-3335.
25. Øynebråten, I., Hansen, B., Smedsrød, B. and Uhlin-Hansen, L. (2000) Serglycin secreted by leucocytes is efficiently eliminated from the circulation by sinusoidal scavanger endothelial cells in the liver.67, pp. 183-188.
26. Bourguignon, L. Y., Gunja-Smith, Z., Iida, N., Zhu, H. B., Young, L. J., Muller, W. J. and Cardiff, R. D. (1998) CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. 176, pp. 206-215.
27. Toyama-Sorimachi, N., Kitamura, F., Habuchi, H., Tobita, Y., Kimata, K. and Miyasaka, M. (1997) Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. 272, pp. 26714-26719.
28. Theocharis, A. D., Seidel, C., Borset, M., Dobra, K., Baykov, V., Labropoulou, V., Kanakis, I., Dalas, E., Karamanos, N. K., Sundan, A. and Hjerpe, A. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. 281, pp. 35116-35128.
29. Zhou, J., Zhu, P., Jiang, J. L., Zhang, Q., Wu, Z. B., Yao, X. Y., Tang, H., Lu, N., Yang, Y. and Chen, Z. N. (2005) Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. 6, p. 25.